DOI
https://doi.org/10.25772/RPK0-T510
Author ORCID Identifier
https://orcid.org/0000-0003-1379-6135
Defense Date
2023
Document Type
Dissertation
Degree Name
Doctor of Philosophy
Department
Pharmaceutical Sciences
First Advisor
Dr. QIngguo Xu
Second Advisor
Dr. Matthew Halquist
Third Advisor
Dr. Charles O'Keefe
Fourth Advisor
Dr. Michael Hindle
Fifth Advisor
Dr. Matthew Banks
Abstract
OUD affects millions of people and induces a significant socio-economic burden. Since 1999, approximately 700,000 lives have been tragically lost, highlighting a profound public health challenge. With the increasing fatalities due to OUD, there is an urgent need for improved therapeutic strategies. Currently, methadone, buprenorphine, and naltrexone are the primary treatments for OUD. However, the daily regimen associated with methadone presents patient adherence challenges, emphasizing the demand for more patient-centric approaches. This study explored LAAM as alternative treatment for OUD, focusing its extended systemic half-life, suggesting potential for thrice-weekly dosing regimen. We invented a novel nanofiber buccal film for transmucosal LAAM delivery, aiming for improved bioavailability and efficacy over the conventional oral LAAM solution (ORLAAM®). The LAAM-loaded nanofiber buccal film formulation is optimized to have immediate drug release, strong mucoadhesive strength, effective buccal mucosa penetration, and good storage stability at ambient conditions. The rabbit pharmacokinetic (PK) studies showed promising results, with the selected formulation (F5) exhibiting 3.5 times higher bioavailability over conventional oral LAAM solutions. Additionally, in vivo efficacy assessment demonstrated that LAAM nanofiber buccal films effectively reduced fentanyl choices in opioid-dependent rats with a thrice-weekly dosing regimen, paralleling the impact of daily methadone treatments. Our findings suggested the promising potential of LAAM-loaded nanofiber buccal films to treat OUD.
Rights
© The Author
Is Part Of
VCU University Archives
Is Part Of
VCU Theses and Dissertations
Date of Submission
12-11-2023
Included in
Nanomedicine Commons, Pharmaceutics and Drug Design Commons, Translational Medical Research Commons